Transcription initiation by RNA polymerase II is regulated by the formation of a preinitiation complex consisting of general transcription factors (reviewed in Refs. 1 and 2). The interaction of the TATA-binding protein (TBP) 1 with promoter DNA is an early and highly regulated step in preinitiation complex assembly at TATA containing promoters (Refs. 3-8 and reviewed in Refs. 9 and 10). Several factors bind directly to TBP and modulate its ability to form an active preinitiation complex. TAF II s and TFIIA bind directly to TBP and are required for transcriptional activation from most promoters in vitro (reviewed in . Both TFIIA and TAF II s can interact directly with promoter-specific activators and mediate their stable interaction with TBP and the preinitiation complex (15-20). TAF II s can bind directly to core promoter sequences and recruit TBP to promoters lacking consensus TATA elements (21-23). TFIIA makes direct contact with DNA sequences upstream of the TATA box of some promoters and stabilizes TBP binding to TATA-containing DNA (24 -27). Thus, both TFIIA and TAF II s can modulate the interactions of TBP with activators, DNA, and other general transcription factors. However, the potential interactions between TFIIA and TAF II s have been less extensively examined and are likely to be an important component of eukaryotic transcriptional regulation.
Transcription initiation by RNA polymerase II is regulated by the formation of a preinitiation complex consisting of general transcription factors (reviewed in Refs. 1 and 2). The interaction of the TATA-binding protein (TBP) 1 with promoter DNA is an early and highly regulated step in preinitiation complex assembly at TATA containing promoters (Refs. [3] [4] [5] [6] [7] [8] and reviewed in Refs. 9 and 10). Several factors bind directly to TBP and modulate its ability to form an active preinitiation complex. TAF II s and TFIIA bind directly to TBP and are required for transcriptional activation from most promoters in vitro (reviewed in Refs. [11] [12] [13] [14] . Both TFIIA and TAF II s can interact directly with promoter-specific activators and mediate their stable interaction with TBP and the preinitiation complex (15) (16) (17) (18) (19) (20) . TAF II s can bind directly to core promoter sequences and recruit TBP to promoters lacking consensus TATA elements (21) (22) (23) . TFIIA makes direct contact with DNA sequences upstream of the TATA box of some promoters and stabilizes TBP binding to TATA-containing DNA (24 -27) . Thus, both TFIIA and TAF II s can modulate the interactions of TBP with activators, DNA, and other general transcription factors. However, the potential interactions between TFIIA and TAF II s have been less extensively examined and are likely to be an important component of eukaryotic transcriptional regulation.
TFIID consists of TBP and at least eight TAF II s (reviewed in Refs. 11 and 14) . TAF II 250 binds directly to TBP and multiple other TAF II s, thus serving as a potential scaffold for the multiprotein complex (28, 29) . Other TAF II s can bind TBP directly, including a subset of TAF II s with homology to histone proteins, which form a histone fold motif (30) . Histones have generally been associated with transcriptional repression by limiting activator and general factor access to promoter sequences, and it is possible that some TAF II s share histone-like features (31) . Purified TAF II 250 has been shown to inhibit the DNA binding activity of TBP (21, 28, 32) . The functional significance of this inhibition has not been well characterized. TAF II 250 is identical to CCG1, a gene identified by a mutation that causes arrest in the G 1 phase of the cell cycle. TAF II 250 has been shown to have both protein kinase and histone acetylase activities, but the functional significance of these activities is not yet clear (33, 34) . Mutations in TBP, which abrogate transcription activation function in vivo, were found to disrupt the ability of TBP to bind to TAF II 250 in vitro (35) . More recent studies in yeast and hamster cell lines indicate that TAF II 250 is required for coordinating the interaction between promoter-specific activators and core promoter elements (36 -39) .
Several lines of evidence indicate that a dynamic interplay between TFIIA and TAF II s regulates the binding of TFIID to promoter DNA. Cross-linking studies indicate that TFIIA significantly alters the interaction of TAF II s with promoter DNA (40) . TFIIA mediates an activator-dependent conformational change in TFIID that results in the interaction of TAF II s with sequences near and downstream of the transcriptional initiation site (20, (41) (42) (43) . The recruitment of TFIIA by an activator significantly enhanced the ability of TFIID to interact with TFIIB, further indicating that TFIIA can alter the properties of TFIID (43) . TFIIA can derepress the inhibitory effects of several factors that bind directly to TBP (5, 44 -47) . The direct binding of TFIIA to TBP is likely to preclude interaction of these inhibitory factors with TBP. The derepression function of TFIIA is mediated by the subunits of TFIIA that contact TBP directly, but these subunits are not sufficient for TFIIA-mediated transcriptional activation function in vitro (48) .
The crystal structure of the yeast TFIIA-TBP-DNA ternary complex reveals that TFIIA makes direct contact with TBP through several hydrophobic residues in the small subunit of TFIIA (Toa2) (26, 27) . Mutagenesis of the homologous residues in the human TFIIA small subunit (␥ ) interrupt TFIIA stimulation of TBP-DNA binding and TFIIA-mediated transcription stimulation in vitro (49) . Interestingly, conservative phenylalanine substitution mutation of these residues (TFIIA ␥ Y65F and W72F) had little detectable effect on the formation of a TFIIA-TBP DNA complex but were found to be defective for transcription activation in vitro (49) . The biochemical basis for these defects was not clear but suggest that subtle changes in the TFIIA-TBP interface have dramatic effects on transcription function. In this work, we further investigated the mechanism underlying the transcription defect caused by these TFIIA mutations. We showed that these mutants are substantially more defective in the presence of TAF II s and that TAF II s are generally inhibitory for TBP-TFIIA complex formation. We also show that the ability of TFIIA to overcome TAF II -mediated inhibition correlates with transcription activation function in vitro.
EXPERIMENTAL PROCEDURES
Plasmid Constructs-The Escherichia coli expression constructs for human wild type and mutant TFIIA-␥ (pRSET A-IIA-␥) and TBP were previously described (49) . The E. coli expression constructs for human TFIIA-␣␤ (pQE-IIA-␣␤) was described previously (20) . Baculovirus expressed human TAF II 250 was kindly provided by R. Tjian (29) . Eukaryotic expression vector for TAF II 250 (pCMV-TAF II 250) was a gift from E. Wang, and Zta was expressed from the SV40 promoter in pBXGo.
Protein Preparations-The pQE-IIA-␣␤ and pRSET A-IIA-␥ wild type or mutant constructs were expressed in M15 and BL21 E. coli strains, respectively. Expressed proteins were purified under denaturing conditions on nickel nitrilotriacetic acid-agarose columns (Qiagen) and dialyzed into D100 buffer as described (20, 49) . Recombinant TFIIA polypeptides were used at a final concentration of ϳ0.2 M for in vitro transcription reactions. Human recombinant TBP and recombinant Zta proteins were prepared as described previously (41) . The GAL4-AH fusion protein was purified as described (50) . Baculovirus-expressed human TAF II 250 was purified from baculovirus-infected cell lysates using the 12CA5 monoclonal antibody for affinity purification and peptide elution essentially as described (51) . Affinity-purified holo-TFIID was purified as described (51) .
DNA Binding Reactions-Polyacrylamide EMSA conditions for T-A complex formation were described (52) . Conditions for Mg 2ϩ -agarose EMSA were described (41, 53) . For Mg 2ϩ -agarose EMSA Zta-hIID-IIA complex formation, 0.2 unit of human IID, 80 nM TFIIA, and 33 nM Zta were used (41) . DNase I footprinting reactions were performed as described previously (54) . For protease experiments, protein and DNA were preincubated for 30 min at 30°C before the addition of 40 ng of protease K for 20 min at 30°C (unless noted otherwise). The relative mobility of the TBP-DNA (T) and TFIIA-TBP-DNA (T-A) complexes varied dramatically in EMSA depending upon the probe used (E1B or E4T) and whether magnesium was included in gels (46, 49) . The positions of T and T-A are indicated in each figure.
In Vitro Transcription Reactions-In vitro transcription reactions contained 100 ng of G 5 E4TCAT template, ϳ200 ng of purified recombinant-GAL4-AH activator protein, and 40 g of TFIIA-depleted HeLa nuclear extract in a 50 l final reaction volume incubated for 1 h at 30°C. Primer extension reactions were described previously (51) . The TFIIA-depleted nuclear extracts were described (20) . Wild-type or mutant pRSET A-IIA-␥ was added back to transcription reactions as described (49) .
Transfection and CAT Assay-The hamster ts13 cell line was purchased from ATCC. Approximately 5 ϫ 10 5 cells were transfected in a 100-mM dish using calcium phosphate precipitation with 250 ng reporter, 5 g of SV-Zta and 30 g of CMV-TAF II 250 (where indicated). Vector DNA was used to compensate for differences in DNA concentration of effector plasmid. Transfected cells were incubated for 8 -12 h at 34°C, washed with phosphate-buffered saline, and then incubated at 34 or 39.5°C as indicated. Cells were harvested for CAT assay 36 to 48 h post-transfection. CAT reactions analyzed by thin layer chromatography and quantitated with a PhosphorImager 445SI screen. All transfections were repeated at least three times.
RESULTS

Mutations in TFIIA Disrupt
Complex Formation with TFIID-In a previous study, we examined a large panel of TFIIA-␥ mutants for the ability to stimulate TBP binding to the adenovirus E1B core promoter and to mediate activator stimulated transcription in vitro. We found that alanine substitution of Tyr-65 completely eliminated the TBP-TFIIA DNA complex (T-A), whereas W72A caused an aberrant migrating complex in acrylamide EMSA. Alanine substitution of these residues and neighboring aromatic residues reduced transcription activation by several activators in vitro (49) . To explore the possible effect of TFIIA mutations on interactions with TAF II s in the TFIID complex, we compared the panel of TFIIA mutants for their ability to support an interaction between the Zta transcriptional activator and TFIID ( Fig. 1 ). Zta stimulates a highly stable interaction between TFIIA, TFIID, and promoter DNA (referred to as the Z-D-A complex) that correlates with transcriptional activation function for a subset of promoters (55) . TFIIA mutants were first tested for their ability to form a stable complex with TBP (referred to as T-A) on the E4T promoter. Under limiting conditions, TBP did not form a stable Mg 2ϩ -agarose EMSA complex by itself but forms a weak smear (Fig. 1A, lane 2) . The addition of wt TFIIA results in a stable well resolved T-A complex (Fig. 1A, lane 3) . Similar stable complexes were resolved for most TFIIA-␥ substitution mutants, with the exception of ␥Y65A, which failed to form T-A (lane 10). Several substitution mutations were reduced for T-A complex formation, and ␥W72A produced a T-A complex with a slower mobility in these Mg 2ϩ -agarose EMSA (Fig. 1A , lane 13 and data not shown). We previously reported an altered mobility complex with the ␥W72A mutant in polyacrylamide-EMSA (49) . These Mg 2ϩ -EMSA results are consistent with previous studies examining the ability of these TFIIA mutants to form a T-A complex with the E1B 30-base pair oligonucleotide in polyacrylamide gel EMSA (49) .
The same panel of TFIIA-␥ mutants were examined for the ability to form Z-D-A by Mg 2ϩ -agarose EMSA. Under conditions where affinity-purified TFIID (hIID) was limiting for DNA binding, wt TFIIA significantly stimulated Z-D-A complex formation (Fig. 1B, lane 2) . Most TFIIA-␥ substitution mutations that support T-A were capable of forming Z-D-A. TFIIA mutant ␥Y65A, which could not form T-A, was similarly incapable of forming Z-D-A (lane 9). Interestingly, ␥Y6A, ␥F67A, ␥C68A, ␥W72A, and ␥F74A were significantly reduced in Z-D-A complex formation. The ␥Y6A, ␥F67A, ␥C68A, ␥W72A, and ␥F74A mutants have defects in mediating regulated transcriptional activity in vitro, indicating that the failure to form Z-D-A correlates with the transcription defects of these TFIIA mutants (49) . Quantitation of complex formation revealed that TFIIA ␥Y6A, ␥F67A, ␥C68A, ␥W72A, and ␥F74A were significantly more disruptive to Z-D-A complex formation compared with T-A complex formation (compare Fig. 1, A and  B) . None of these TFIIA-␥ mutants disrupted the interaction with Zta in a glutathione S-transferase binding assay, suggesting that failure to form Z-D-A is a result of a failure of TFIIA to interact properly with TFIID (data not shown). The fact that these mutations were more defective with TFIID than with TBP raised the possibility that some of these TFIIA mutations were incapable of interacting with TBP in the presence of TAF II s.
To further investigate the possible effect of TAF II s on TFIIA association with TBP, we examined the properties of TFIIA mutants that specifically alter the TFIIA-TBP interface. Based on the crystal structure of the yeast TFIIA-TBP-DNA ternary structure, conserved human residues TFIIA-␥Tyr-65 and ␥ Trp-72 are likely to make direct contact with TBP. Our previous analysis indicated that semiconservative substitution mutants TFIIA ␥Y65F and ␥W72F were able to stimulate T-A complex formation at nearly wt levels on a 30-base pair adenovirus E1B oligonucleotide in EMSA (Fig. 2B) (49) . However, these mutants were defective in mediating regulated transcriptional activation for the GAL4-CTF, -AH, and -VP16 activators on the G 5 E1BTCAT template and AP1 on the collagenase promoter in vitro (49) . In this study, the TFIIA ␥-W72A and Phe mutants were also shown to be incapable of coactivating transcription from the G 5 E4TCAT reporter with the GAL4-AH activator in vitro (Fig. 2C) . Thus, these TFIIA mutants are defective for transcriptional activation on two different core promoters. Because these mutants were capable of forming T-A but were defective in mediating transcriptional activation, we suspected they may be incapable of interacting with TFIID. The ability of these mutants to interact with TFIID was tested by comparing their ability to form complexes with TBP, TFIID, or TFIID and Zta in Mg 2ϩ -agarose EMSA ( Fig. 2A) . The ␥Y65F and ␥W72F mutants stimulate T-A formation in Mg 2ϩ -agarose EMSA ( Fig. 2A, lanes 4 and 6) , just as they do in the polyacrylamide EMSA (Fig. 2B, lanes 3 and 5) (49) . Both the Trp-72 mutants formed a slower, altered mobility complex in polyacrylamide EMSA as in the Mg 2ϩ -agarose gel EMSA ( Fig. 2A,  lanes 5 and 6) . However, these TFIIA mutants were completely defective in forming stable complexes with TFIID in the absence (lanes 9 -11) or presence (lanes 15-17) of the Zta transcriptional activator. Thus, the TAF II s in TFIID inhibit these TFIIA mutants from forming a stable complex with TBP. Moreover, the failure of these mutants to form stable complexes with TFIID correlates with their defects in transcriptional activation function (Fig. 2C) (49) .
Phenylalanine Substitution of Tyr-65 Decreases Stability of T-A-
The semiconservative substitutions at residues Tyr-65 and Trp-72 were particularly interesting because these form T-A but were defective for D-A formation and transcriptional coactivation (Fig. 2) (49) . Based on crystal structure, we would predict that mutations at these residues should have a primary defect in the interaction with TBP. To determine whether these TFIIA mutants alter the stability of the T-A complex, we compared the dissociation rate of T-A formed with the wild-type and mutant TFIIAs. Dissociation rates were measured in polyacrylamide EMSA by the addition of excess unlabeled TATA oligonucleotide competitor to preformed T-A-DNA complexes (Fig. 3A) . T-A complex stability was assayed at increasing times after the addition of competitor TATA oligonucleotide. We found that ␥ Y65F had a significantly increased dissocia- 
tion rate relative to wild-type TFIIA because there was an ϳ8-fold difference in the reduction of T-A complex after 4 h of oligonucleotide challenge relative to the reduction of complex formed with wild-type IIA (Fig. 3A, lanes 18 and 19) . In contrast, the ␥ W72A mutant showed no significant change in the dissociation rate relative to wild-type TFIIA after 4 h of oligonucleotide challenge (Fig. 3A) . Thus, the transcriptional defect of ␥ Y65F may be attributed, in part, to decreasing the stability of the T-A-DNA ternary complex.
Substitutions at Trp-72 Increase Protease Sensitivity of T-A-Mutations at residue Trp-72 produce a stable T-A complex but often give rise to a species of slower mobility. To explore the possibility that TFIIA-␥W72A and ␥W72F may produce alternative conformations in the ternary complex with TBP and DNA, we used limited proteolysis as a probe of protein structure and stability. Limited proteolysis has been used previously to map a core domain of TBP and TFIIA and for evidence that TFIIA induces a conformational change in TBP (54, 56, 57) . Treatment of TBP with protease K resulted in a slight stimulation of DNA binding and a faster mobility in acrylamide EMSA (Fig. 3B, lane 1 to lanes 6, 11, and 16) . Treatment of T-A complexes formed with wt TFIIA resulted in a stable faster migrating complex (Fig. 3B, compare lane 2 to lanes 7, 12, and  17) . Interestingly, complexes formed with either ␥W72A or ␥ W72F resulted in nearly complete digestion of the T-A complex, with an 8-fold reduction of complex formation compared with wild-type T-A (Fig. 3B) . In contrast, the complex formed with ␥ Y65F was as protease-resistant as wt TFIIA (Fig. 3B) . Digestion of TBP before DNA binding resulted in the complete loss of binding activity, similar to what was seen for the ␥Trp-72 mutants (Ref. 54 and data not shown). These results show that both TBP and TFIIA-TBP assume a stable and protease-resistant conformation once bound to DNA. The ␥Trp-72 mutants failed to form the protease-resistant complex and also failed to stimulate transcriptional activation, suggesting that the protease-resistant conformation is important for transcription activation function. We suggest that ␥Trp-72 mutants trap TBP in an inactive conformation and that this conformation may occur under natural conditions in vivo. Conformational changes in TBP may be the mechanistic basis for some transcriptional regulatory pathways.
Proteolysis Stimulates TFIID-DNA and TFIID-IIA Binding-To further explore the effect of TAF II s on TFIIA-TBP and TBP-DNA binding, we tested the effects of limited proteolysis on the behavior of TFIID in DNA binding reactions with or without TFIIA (Fig. 4A) . Despite the large molecular mass of the TFIID complex, TFIID-DNA complexes could be partially resolved in Mg 2ϩ -acrylamide EMSA (Fig. 4A, lane 2) . The addition of protease K (40 ng) for 20 min resulted in a striking stimulation of DNA binding activity in this assay (lane 3). Some of this stimulation may result from the degradation of TAF II s that prevent TFIID-DNA from entering acrylamide gels. In contrast, recombinant TBP bound to similar amounts of DNA (lane 6) but was only modestly stimulated by treatment with protease K (lane 7). The addition of TFIIA to TFIID resulted in a significant stimulation of DNA binding (compare lanes 2 and 4) . Interestingly, the addition of protease further stimulated the TFIIA-TFIID complex as well as increased the and 8) . Protease K treatment increased the mobility of the TBP-TFIIA complex but had only a minor stimulatory effect on the amount of complex formed (lane 9). One interpretation of this result is that protease degrades TAF II s, which inhibit TFIIA and DNA interactions with TFIID. Curiously, TFIIDand TBP-containing complexes had identical mobilities both before and after protease treatment. Previous work has also found similar mobilities between TBP and TFIID in EMSA, which may be accounted for by the unusual conformational constraints imposed on DNA bound by TBP (41, 53) .
Limited proteolysis of TFIID may affect one or more components in the TFIID multiprotein complex. To determine whether at least one TAF was affected by limited proteolysis, we assayed proteolyzed TFIID by Western blotting with antibody specific for TAF II 250 (Fig. 4B) . TFIID was treated with protease K under conditions that were previously found to stimulate DNA binding activity. At the lowest concentration of protease K treatment (1 ng), we found that TAF II 250 was partially degraded, indicating it is highly sensitive to proteolytic cleavage. With 10 ng of protease, TAF II 250 was no longer detectable, indicating that recognizable epitopes had been completely degraded. Stimulation of DNA binding was observed with 40 ng of protease K (Fig. 4A) , suggesting that TAF II 250 was mostly degraded in those reactions. These results indicate that TAF II 250 is a candidate target of proteolysis in reactions where TBP-DNA binding is stimulated.
To further characterize the protease stimulation of TFIID-DNA and TFIIA-TFIID-DNA binding, we assayed partially proteolyzed complexes by DNase I footprinting assay. The DNase I footprinting assay should eliminate destabilizing effects imposed by gel electrophoresis, a phenomenon previously observed for TBP-DNA interactions (54) . Using similar protein-DNA binding and proteolysis conditions, we found that proteolysis had a modest stimulatory effect (ϳ2.4-fold) on TFIID protection (Fig. 5A, compare lanes 2 and 3) . In contrast, proteolysis had a much larger stimulatory effect (ϳ7.7-fold) on TFIIA-TFIID binding to the TATA element (Fig. 5A, lanes 4  and 5) . Proteolysis had only a slight stimulatory effect on TBP (ϳ1.3-fold) and TFIIA-TBP (ϳ1.4-fold) binding to the TATA box (Fig. 5B) . Although these results support the observations presented in Fig. 4 , they suggest that the stimulation of TFIID binding to TATA is partly dependent upon the gel assay, suggesting that proteolysis stabilizes the protein-DNA interaction against the disruptive effects of gel electrophoresis observed in Fig. 4 . On the other hand, the DNase I assay also supports the observation that proteolysis stimulates TFIIA-TFIID-DNA binding in solution. (Fig. 6) . Others have shown that the addition of recombinant TAF II 250 to recombinant TBP results in an inhibition of TATA binding activity (28, 32) . TFIIA binds directly to TBP and can preclude the interaction of TBP with several transcriptional inhibitors (44 -47) . To determine if TFIIA could prevent the TAF II 250 inhibition of TBP-TATA binding, we initially determined whether addition of TAF II 250 could inhibit DNA binding of preformed T-A complexes (Fig. 6) . Incubation of TBP with TFIIA resulted in a strong stimulation of DNA binding (Fig. 6A, lane 3) . When TFIIA was preincubated with TBP for 15 min followed by the addition of TAF II 250, TFIIA-TBP-DNA complex formation was reduced only slightly, indicating that this complex was largely resistant to TAF II 250-mediated repression (lane 4). In contrast, if TAF II 250 was preincubated with TBP for 15 min followed by the addition of TFIIA, DNA binding was abolished (Fig. 6A,  lane 5) . A time course of preincubation with TFIIA-TBP-DNA was performed to determine how much time was required to establish a stable TAF II 250-resistant TFIIA-TBP-DNA complex (Fig. 6B) . We found that simultaneous addition of TAF II 250 and TFIIA to TBP and DNA resulted in a significant inhibition of DNA binding (Fig. 6B, lane 4) . However, after 15 min of preincubation with TFIIA, TBP, and DNA, a stable complex formed that was resistant to TAF II 250 inhibition (lane 6). Thus, TFIIA competes with TAF II 250 for interaction with TBP, and the resulting complexes have opposite effects on the DNA binding properties of TBP.
Mutant TAF II 250 Enhances Transcription By an Activator in Vivo-
To determine what effect TAF II 250 inhibition of TBP-DNA or TBP-TFIIA complexes have on transcription activator function, we assayed Zta-mediated transcriptional activation in the ts13 cell line at permissive and nonpermissive temperatures (Fig. 7) . The ts13 cell line contains a mutated TAF II 250 gene, which results in G 1 cell cycle arrest at nonpermissive temperatures (39.5°C). Transfection of Zta resulted in ϳ15-fold level of activation in the ts13 cell line at the permissive temperature (34°C) on the Z 5 E4TCAT reporter plasmid. In and 7) , or TBP plus TFIIA (lanes 8 and 9) were bound to the Ad E4 core promoter for 30 min. Samples in lanes 3, 5, 7, and 9 were then treated with 40 ng of protease K for 20 min. Samples were electrophoresed on 6% polyacrylamide gels containing 5 mM magnesium acetate. B, TAF II 250 is highly sensitive to limited proteolysis. The TFIID fraction was incubated with increasing concentrations (1, 10, or 100 ng) of protease K as indicated above. The integrity of TAF II 250 was analyzed by Western blotting and probing with monoclonal antibody directed against TAF II 250 (Santa Cruz Biotechnology).
contrast, transfection of Zta resulted in a ϳ42-fold level of activation in ts13 cells at the nonpermissive temperature (Fig.  7A) . Activator levels were not effected by temperature shift in ts13 cells, and a similar temperature shift had no effect on transactivation levels in control baby hamster kidney cell lines (data not shown). Furthermore, a temperature shift resulted in a slight decrease in basal level transcription, indicating that temperature shift by itself did not produce a generalized increase in CAT activity (data not shown). Similar increased transcriptional effects were observed with TAF II 250 inactivation in ts13 cells using a different reporter promoter (BHLF1) with Zta or a different activator (GAL4-VP16) with the G 5 E4TCAT reporter (data not shown). This suggests that the transcriptional effect is not specific for the Zta activator or the template. To determine if this transcriptional enhancement was a result of the mutated TAF II 250 gene, wild-type TAF II 250 was cotransfected with Zta and reporter plasmids in ts13 cells (Fig. 7B) . Cotransfection of wild-type TAF II 250 reduced Zta activation levels at the nonpermissive temperature to levels similar to that observed at the permissive temperature. Thus, introduction of wild-type TAF II 250 partially reversed the enhancement of activation caused by temperature shift, suggesting that mutant TAF II 250 is responsible for the Zta-dependent transcriptional enhancement. Although these transfection experiments do not address the direct role of TAF II 250 in transcription function, they do provide indirect evidence to suggest that TAF II 250 can inhibit transcription function by an activator in vivo.
DISCUSSION
Although the interaction of TFIIA with TBP has been well characterized, relatively little is understood of how TAF II s may alter the interaction of TFIIA with TBP in the TFIID complex. In this work, we have investigated the effect of TAF II s on the interaction of TFIIA with TBP. Several different experimental approaches were used to demonstrate that TAF II s can inhibit the binding of TBP with TFIIA and DNA. We have shown that a subset of TFIIA mutations is more defective for interaction with TFIID than with TBP, suggesting that TAF II s can destabilize interactions between TBP and TFIIA ( Figs. 1 and 2 ). Limited proteolysis of TFIID markedly stimulated DNA binding which suggests that degradation of TAF II s may alleviate repression of TFIID-DNA binding activity (Figs. 4 and 5) . Limited proteolysis also stimulated the amount of D-A complex formed, further suggesting that TAF II s may also inhibit TFIIA from binding TBP. Purified human TAF II 250 was found to inhibit T-A complex formation, demonstrating that at least one TAF II precludes the interaction between TFIIA and TBP (Fig.  6) . Finally, we show that transcription activation by Zta can be enhanced in vivo by the inactivation of TAF II 250 in ts13 cell lines by shifting to the nonpermissive temperature (Fig. 7) . Taken together, these results suggest that TAF II s can regulate transcription by inhibiting TBP interactions with TFIIA and DNA.
We have found that a subset of TFIIA mutations are more defective for interaction with TFIID than with TBP ( Figs. 1 and  2 ). Phenylalanine substitution mutations at ␥Tyr-65 and Trp-72 were capable of forming a stable T-A complex in both Mg 2ϩ -agarose and polyacrylamide EMSA but were defective in forming a stable EMSA complex with TFIID (Fig. 2) . These mutants were also incapable of supporting activated transcription in vitro, indicating that TFIIA must associate with TFIID to function in transcription (Fig. 2) . Further examination of these mutations revealed that they formed an aberrant T-A complex, with either an increased dissociation rate (␥Y65F) or increased protease sensitivity (␥W72F and W72A) (Fig. 3) . Thus, subtle changes in the stability or conformation of the T-A complex were sufficient to disrupt association with TFIID and inhibit transcription activation function. The TAF II s further destabilize the association of these TFIIA mutants with TBP, thus revealing an inhibitory effect on TFIIA assembly. Additionally, these TFIIA mutants may fail to induce changes in the TAF II configuration necessary for TFIIA-TFIID-DNA complex formation to occur. In either case, a stable interaction between TFIIA and TBP appears essential to overcome TAF II inhibition of TFIID-DNA binding.
The potential inhibitory role of TAF II s on TFIID binding was further supported by the stimulation of TFIID-DNA binding by limited proteolysis (Figs. 4 and 5) . We found limited proteolysis stimulated D-A complex formation significantly better than T-A complex formation. Earlier work has shown that limited proteolysis could stimulate TBP-DNA binding, and this was largely a result of the degradation of the nonconserved aminoterminal domain of TBP (54, 56, 58) . Moreover, the addition of TFIIA was shown to bypass the need for the proteolysis of TBP, suggesting that TFIIA stimulated a conformational change in the amino-terminal domain of TBP (56). Our results do not exclude the possibility that stimulation of DNA binding by TFIIA involves a conformational change in the TBP aminoterminal domain. Recent findings indicate that the inhibition of DNA binding by the amino-terminal domain can be relieved by interaction with the SNAP complex, which is required for activation of the U6 gene (58) . The configuration of the aminoterminal domain in the TFIID complex is unknown, and it is possible that TAF II s may increase its inhibitory effect on TBP-DNA binding.
The limited proteolysis experiments suggest that some TAF II s in the native TFIID complex inhibit TBP-DNA binding (Figs. 4 and 5) . TAF II 250 has been shown by others to inhibit TBP binding to DNA (21, 28, 32) . Because the addition of recombinant TAF II 250 to TBP does not necessarily reconstitute the physiological properties of the entire TFIID complex, it was important to demonstrate that TAF II s have inhibitory activities in the context of the native TFIID complex. TAF II 250 was highly sensitive to proteolysis in the TFIID complex and thus qualifies as a candidate target of protease-mediated stimulation of TFIID-DNA binding (Fig. 4B) . We have also shown that purified TAF II 250 can inhibit T-A complex formation and that preincubation of TFIIA with TBP reverses this inhibition (Fig.  6) (59, 60) . TFIIA inhibits the cross-linking of human TAF II 55 and p31 to promoter sequences upstream of the TATA element and enhances the cross-linking of TAF II 250 and TAF II 135 to sequences downstream of the adenovirus major late promoter TATA element (40) . TFIIA is required for an activator-mediated conformational change in TFIID that results in an enhanced interaction downstream of the transcriptional initiation site (20, 41) . Together, these results indicate that TFIIA can bind to and alter the organization of TAF II s in the TFIID complex. Although it is possible that TFIIA may dissociate TAF II 250 from TBP, it is likely that TAF II 250 remains associated with the TFIIA-TFIID-promoter complex by its association with multiple other TAFs in the TFIID complex.
The yeast homologue of TAF II 250 also dissociated TBP from DNA and prevented TFIIA binding to TBP (61, 62) . A partially conserved amino-terminal domain of yTAF II 145 bound directly to TBP and was required for the inhibition of TBP-DNA and TBP-TFIIA binding. Interestingly, an amino-terminal deletion mutation of yTAF II 145 was found to be temperature-sensitive in yeast, and this conditional lethality could be rescued by overexpression of TFIIA subunits (62) . This latter result suggests that TFIIA and the amino-terminal domain of yTAF II 145 function cooperatively and not antagonistically as might be predicted from the in vitro binding studies. yTAF II 145 may inhibit TBP binding and TFIIA access but nevertheless stabilizes these associations once formed in vivo. These results emphasize the potential complexity of interactions between TFIID, TFIIA, and activators. Furthermore, representational display analysis of transcripts from yeast cells grown under nonpermissive conditions for yTAF II 145 reveal that an equal number of transcripts were enhanced compared with the numbers that were diminished (38) . This is consistent with a role of yTAF II 145 in transcriptional repression as well as coactivation for some genes in yeast. Our data suggest that mammalian TAF II 250 has similar activities involved in the inhibition of transcription for some activators and/or promoters in vivo. We suggest that the inhibition of TFIIA-TBP-DNA complex formation by TAF II 250 may be one mechanism by which TAF II 250 regulates gene expression. Activators like Zta may facilitate conformational changes and/or displacement of TAF II 250 that allow TFIIA to bind TBP and promote active preinitiation complex formation.
